DAB2_HUMAN - dbPTM
DAB2_HUMAN - PTM Information in dbPTM
Basic Information of Protein
UniProt ID DAB2_HUMAN
UniProt AC P98082
Protein Name Disabled homolog 2
Gene Name DAB2
Organism Homo sapiens (Human).
Sequence Length 770
Subcellular Localization Cytoplasm. Cytoplasmic vesicle, clathrin-coated vesicle membrane. Membrane, clathrin-coated pit. Colocalizes with large insert-containing isoforms of MYO6 at clathrin-coated pits/vesicles. During mitosis is progressively displaced from the membrane a
Protein Description Adapter protein that functions as clathrin-associated sorting protein (CLASP) required for clathrin-mediated endocytosis of selected cargo proteins. Can bind and assemble clathrin, and binds simultaneously to phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) and cargos containing non-phosphorylated NPXY internalization motifs, such as the LDL receptor, to recruit them to clathrin-coated pits. Can function in clathrin-mediated endocytosis independently of the AP-2 complex. Involved in endocytosis of integrin beta-1; this function seems to redundant with the AP-2 complex and seems to require DAB2 binding to endocytosis accessory EH domain-containing proteins such as EPS15, EPS15L1 and ITSN1. Involved in endocytosis of cystic fibrosis transmembrane conductance regulator/CFTR. Involved in endocytosis of megalin/LRP2 lipoprotein receptor during embryonal development. Required for recycling of the TGF-beta receptor. Involved in CFTR trafficking to the late endosome. Involved in several receptor-mediated signaling pathways. Involved in TGF-beta receptor signaling and facilitates phosphorylation of the signal transducer SMAD2. Mediates TFG-beta-stimulated JNK activation. May inhibit the canoniocal Wnt/beta-catenin signaling pathway by stabilizing the beta-catenin destruction complex through a competing association with axin preventing its dephosphorylation through protein phosphatase 1 (PP1). Sequesters LRP6 towards clathrin-mediated endocytosis, leading to inhibition of Wnt/beta-catenin signaling. May activate non-canonical Wnt signaling. In cell surface growth factor/Ras signaling pathways proposed to inhibit ERK activation by interrupting the binding of GRB2 to SOS1 and to inhibit SRC by preventing its activating phosphorylation at 'Tyr-419'. Proposed to be involved in modulation of androgen receptor (AR) signaling mediated by SRC activation; seems to compete with AR for interaction with SRC. Plays a role in the CSF-1 signal transduction pathway. Plays a role in cellular differentiation. Involved in cell positioning and formation of visceral endoderm (VE) during embryogenesis and proposed to be required in the VE to respond to Nodal signaling coming from the epiblast. Required for the epithelial to mesenchymal transition, a process necessary for proper embryonic development. May be involved in myeloid cell differentiation and can induce macrophage adhesion and spreading. May act as a tumor suppressor..
Protein Sequence MSNEVETSATNGQPDQQAAPKAPSKKEKKKGPEKTDEYLLARFKGDGVKYKAKLIGIDDVPDARGDKMSQDSMMKLKGMAAAGRSQGQHKQRIWVNISLSGIKIIDEKTGVIEHEHPVNKISFIARDVTDNRAFGYVCGGEGQHQFFAIKTGQQAEPLVVDLKDLFQVIYNVKKKEEEKKKIEEASKAVENGSEALMILDDQTNKLKSGVDQMDLFGDMSTPPDLNSPTESKDILLVDLNSEIDTNQNSLRENPFLTNGITSCSLPRPTPQASFLPENAFSANLNFFPTPNPDPFRDDPFTQPDQSTPSSFDSLKSPDQKKENSSSSSTPLSNGPLNGDVDYFGQQFDQISNRTGKQEAQAGPWPFSSSQTQPAVRTQNGVSEREQNGFSVKSSPNPFVGSPPKGLSIQNGVKQDLESSVQSSPHDSIAIIPPPQSTKPGRGRRTAKSSANDLLASDIFAPPVSEPSGQASPTGQPTALQPNPLDLFKTSAPAPVGPLVGLGGVTVTLPQAGPWNTASLVFNQSPSMAPGAMMGGQPSGFSQPVIFGTSPAVSGWNQPSPFAASTPPPVPVVWGPSASVAPNAWSTTSPLGNPFQSNIFPAPAVSTQPPSMHSSLLVTPPQPPPRAGPPKDISSDAFTALDPLGDKEIKDVKEMFKDFQLRQPPAVPARKGEQTSSGTLSAFASYFNSKVGIPQENADHDDFDANQLLNKINEPPKPAPRQVSLPVTKSTDNAFENPFFKDSFGSSQASVASSQPVSSEMYRDPFGNPFA
Overview of Protein Modification Sites with Functional and Structural Information
Experimental Post-Translational Modification Sites

* ASA = Accessible Surface Area

Locations Modification Substrate Peptides
&
Secondary Structure
ASA (%) Reference Orthologous
Protein Cluster
2Acetylation------MSNEVETSA
------CCCCCCCCC
41.5219413330
2Phosphorylation------MSNEVETSA
------CCCCCCCCC
41.5222199227
7Phosphorylation-MSNEVETSATNGQP
-CCCCCCCCCCCCCC
28.9225159151
8PhosphorylationMSNEVETSATNGQPD
CCCCCCCCCCCCCCC
21.4227486199
10PhosphorylationNEVETSATNGQPDQQ
CCCCCCCCCCCCCCC
39.3827486199
24PhosphorylationQAAPKAPSKKEKKKG
CCCCCCCCHHHHCCC
62.3128842319
34UbiquitinationEKKKGPEKTDEYLLA
HHCCCCCCCCHHHHH
65.49-
38PhosphorylationGPEKTDEYLLARFKG
CCCCCCHHHHHHHCC
15.1527642862
53MalonylationDGVKYKAKLIGIDDV
CCCEEEEEEECCCCC
36.1626320211
53UbiquitinationDGVKYKAKLIGIDDV
CCCEEEEEEECCCCC
36.16-
64MethylationIDDVPDARGDKMSQD
CCCCCCCCCCCCCHH
62.31-
67AcetylationVPDARGDKMSQDSMM
CCCCCCCCCCHHHHH
43.197672303
67UbiquitinationVPDARGDKMSQDSMM
CCCCCCCCCCHHHHH
43.19-
69PhosphorylationDARGDKMSQDSMMKL
CCCCCCCCHHHHHHH
36.2520873877
72PhosphorylationGDKMSQDSMMKLKGM
CCCCCHHHHHHHHHH
17.0920873877
77UbiquitinationQDSMMKLKGMAAAGR
HHHHHHHHHHHHCCC
40.91-
98PhosphorylationQRIWVNISLSGIKII
CCEEEEEECCCEEEE
15.98-
100PhosphorylationIWVNISLSGIKIIDE
EEEEEECCCEEEEEC
31.51-
108UbiquitinationGIKIIDEKTGVIEHE
CEEEEECCCCCEECC
47.00-
120UbiquitinationEHEHPVNKISFIARD
ECCCCCCEEEEEEEC
39.70-
151PhosphorylationHQFFAIKTGQQAEPL
EEEEEEEECCCCCCE
33.8222817900
163MethylationEPLVVDLKDLFQVIY
CCEEEEHHHHHHHHH
48.17-
170PhosphorylationKDLFQVIYNVKKKEE
HHHHHHHHHCCCHHH
18.2925159151
173MethylationFQVIYNVKKKEEEKK
HHHHHHCCCHHHHHH
55.26-
193PhosphorylationSKAVENGSEALMILD
HHHHHHCCCEEEEEE
31.1425159151
197SulfoxidationENGSEALMILDDQTN
HHCCCEEEEEEHHHC
3.5430846556
203PhosphorylationLMILDDQTNKLKSGV
EEEEEHHHCCCCCCC
41.1228555341
208PhosphorylationDQTNKLKSGVDQMDL
HHHCCCCCCCCHHHH
55.2623403867
220PhosphorylationMDLFGDMSTPPDLNS
HHHCCCCCCCCCCCC
42.3725159151
221PhosphorylationDLFGDMSTPPDLNSP
HHCCCCCCCCCCCCC
32.0025159151
227PhosphorylationSTPPDLNSPTESKDI
CCCCCCCCCCCCCCE
40.2625159151
229PhosphorylationPPDLNSPTESKDILL
CCCCCCCCCCCCEEE
53.3525159151
231PhosphorylationDLNSPTESKDILLVD
CCCCCCCCCCEEEEE
37.8025159151
241PhosphorylationILLVDLNSEIDTNQN
EEEEECCCCCCCCCC
43.1320873877
245PhosphorylationDLNSEIDTNQNSLRE
ECCCCCCCCCCCCCC
44.3528060719
249PhosphorylationEIDTNQNSLRENPFL
CCCCCCCCCCCCCCC
21.0227535140
262PhosphorylationFLTNGITSCSLPRPT
CCCCCCCCCCCCCCC
10.3725627689
264PhosphorylationTNGITSCSLPRPTPQ
CCCCCCCCCCCCCCC
40.9725159151
301PhosphorylationPFRDDPFTQPDQSTP
CCCCCCCCCCCCCCC
44.5823663014
306PhosphorylationPFTQPDQSTPSSFDS
CCCCCCCCCCCCHHH
50.0623663014
307PhosphorylationFTQPDQSTPSSFDSL
CCCCCCCCCCCHHHC
22.8923663014
309PhosphorylationQPDQSTPSSFDSLKS
CCCCCCCCCHHHCCC
43.6623663014
310PhosphorylationPDQSTPSSFDSLKSP
CCCCCCCCHHHCCCC
33.9923663014
313PhosphorylationSTPSSFDSLKSPDQK
CCCCCHHHCCCCCCC
35.3723663014
315UbiquitinationPSSFDSLKSPDQKKE
CCCHHHCCCCCCCCC
64.99-
316PhosphorylationSSFDSLKSPDQKKEN
CCHHHCCCCCCCCCC
38.7223663014
321UbiquitinationLKSPDQKKENSSSSS
CCCCCCCCCCCCCCC
57.40-
324PhosphorylationPDQKKENSSSSSTPL
CCCCCCCCCCCCCCC
32.4623663014
325PhosphorylationDQKKENSSSSSTPLS
CCCCCCCCCCCCCCC
45.9123663014
326PhosphorylationQKKENSSSSSTPLSN
CCCCCCCCCCCCCCC
28.2923663014
327PhosphorylationKKENSSSSSTPLSNG
CCCCCCCCCCCCCCC
39.9323663014
328PhosphorylationKENSSSSSTPLSNGP
CCCCCCCCCCCCCCC
35.6723663014
329PhosphorylationENSSSSSTPLSNGPL
CCCCCCCCCCCCCCC
30.1423663014
332PhosphorylationSSSSTPLSNGPLNGD
CCCCCCCCCCCCCCC
40.7323663014
335 (in isoform 3)Ubiquitination-27.23-
342PhosphorylationPLNGDVDYFGQQFDQ
CCCCCCCHHHHHHHH
14.9523663014
356UbiquitinationQISNRTGKQEAQAGP
HHHCCCCCHHHHCCC
44.33-
367PhosphorylationQAGPWPFSSSQTQPA
HCCCCCCCCCCCCCC
25.6325159151
368PhosphorylationAGPWPFSSSQTQPAV
CCCCCCCCCCCCCCE
27.1825627689
369PhosphorylationGPWPFSSSQTQPAVR
CCCCCCCCCCCCCEE
35.7325159151
371PhosphorylationWPFSSSQTQPAVRTQ
CCCCCCCCCCCEECC
38.1721712546
390PhosphorylationEREQNGFSVKSSPNP
HHHHCCCCCCCCCCC
29.9925159151
392UbiquitinationEQNGFSVKSSPNPFV
HHCCCCCCCCCCCCC
43.98-
393PhosphorylationQNGFSVKSSPNPFVG
HCCCCCCCCCCCCCC
49.2025463755
394PhosphorylationNGFSVKSSPNPFVGS
CCCCCCCCCCCCCCC
23.9925463755
401PhosphorylationSPNPFVGSPPKGLSI
CCCCCCCCCCCCCEE
32.5019664994
407O-linked_GlycosylationGSPPKGLSIQNGVKQ
CCCCCCCEECCCCHH
30.6930059200
407PhosphorylationGSPPKGLSIQNGVKQ
CCCCCCCEECCCCHH
30.6927251789
418PhosphorylationGVKQDLESSVQSSPH
CCHHHHHHHHCCCCC
43.0123663014
419PhosphorylationVKQDLESSVQSSPHD
CHHHHHHHHCCCCCC
18.1423663014
422PhosphorylationDLESSVQSSPHDSIA
HHHHHHCCCCCCCEE
43.6222167270
423PhosphorylationLESSVQSSPHDSIAI
HHHHHCCCCCCCEEE
14.7922167270
427PhosphorylationVQSSPHDSIAIIPPP
HCCCCCCCEEEECCC
15.7522167270
436PhosphorylationAIIPPPQSTKPGRGR
EEECCCCCCCCCCCC
44.1425159151
437PhosphorylationIIPPPQSTKPGRGRR
EECCCCCCCCCCCCC
35.6922817900
438UbiquitinationIPPPQSTKPGRGRRT
ECCCCCCCCCCCCCC
51.20-
448PhosphorylationRGRRTAKSSANDLLA
CCCCCCCCHHHHHHH
32.0220068231
449PhosphorylationGRRTAKSSANDLLAS
CCCCCCCHHHHHHHH
30.3120873877
456PhosphorylationSANDLLASDIFAPPV
HHHHHHHHCCCCCCC
31.0720068231
464PhosphorylationDIFAPPVSEPSGQAS
CCCCCCCCCCCCCCC
49.9523663014
467PhosphorylationAPPVSEPSGQASPTG
CCCCCCCCCCCCCCC
39.2123663014
471PhosphorylationSEPSGQASPTGQPTA
CCCCCCCCCCCCCCC
18.3323663014
473PhosphorylationPSGQASPTGQPTALQ
CCCCCCCCCCCCCCC
46.0523663014
477PhosphorylationASPTGQPTALQPNPL
CCCCCCCCCCCCCCC
31.9223663014
633PhosphorylationAGPPKDISSDAFTAL
CCCCCCCCCCCCHHC
32.0922199227
634PhosphorylationGPPKDISSDAFTALD
CCCCCCCCCCCHHCC
33.0429214152
638PhosphorylationDISSDAFTALDPLGD
CCCCCCCHHCCCCCC
28.2123186163
646UbiquitinationALDPLGDKEIKDVKE
HCCCCCCHHHHHHHH
60.59-
652UbiquitinationDKEIKDVKEMFKDFQ
CHHHHHHHHHHHHCC
54.30-
670UbiquitinationPPAVPARKGEQTSSG
CCCCCCCCCCCCCCC
69.75-
674PhosphorylationPARKGEQTSSGTLSA
CCCCCCCCCCCHHHH
22.1321945579
675PhosphorylationARKGEQTSSGTLSAF
CCCCCCCCCCHHHHH
26.8521945579
676PhosphorylationRKGEQTSSGTLSAFA
CCCCCCCCCHHHHHH
38.9021945579
678O-linked_GlycosylationGEQTSSGTLSAFASY
CCCCCCCHHHHHHHH
21.3530059200
678PhosphorylationGEQTSSGTLSAFASY
CCCCCCCHHHHHHHH
21.3521945579
680PhosphorylationQTSSGTLSAFASYFN
CCCCCHHHHHHHHHH
22.6021945579
684PhosphorylationGTLSAFASYFNSKVG
CHHHHHHHHHHHCCC
24.6521945579
685PhosphorylationTLSAFASYFNSKVGI
HHHHHHHHHHHCCCC
11.8921945579
688PhosphorylationAFASYFNSKVGIPQE
HHHHHHHHCCCCCHH
20.8621945579
723O-linked_GlycosylationKPAPRQVSLPVTKST
CCCCCCEECCEECCC
20.7230059200
723PhosphorylationKPAPRQVSLPVTKST
CCCCCCEECCEECCC
20.7225463755
727O-linked_GlycosylationRQVSLPVTKSTDNAF
CCEECCEECCCCCCC
19.8230059200
727PhosphorylationRQVSLPVTKSTDNAF
CCEECCEECCCCCCC
19.8225463755
728UbiquitinationQVSLPVTKSTDNAFE
CEECCEECCCCCCCC
52.14-
729O-linked_GlycosylationVSLPVTKSTDNAFEN
EECCEECCCCCCCCC
31.4630059200
729PhosphorylationVSLPVTKSTDNAFEN
EECCEECCCCCCCCC
31.4630266825
730O-linked_GlycosylationSLPVTKSTDNAFENP
ECCEECCCCCCCCCC
34.5230059200
730PhosphorylationSLPVTKSTDNAFENP
ECCEECCCCCCCCCC
34.5230266825
742PhosphorylationENPFFKDSFGSSQAS
CCCCHHCCCCCCCHH
31.9028450419
745PhosphorylationFFKDSFGSSQASVAS
CHHCCCCCCCHHHHC
19.7828450419
746PhosphorylationFKDSFGSSQASVASS
HHCCCCCCCHHHHCC
30.0928450419
749O-linked_GlycosylationSFGSSQASVASSQPV
CCCCCCHHHHCCCCC
15.5830059200
749PhosphorylationSFGSSQASVASSQPV
CCCCCCHHHHCCCCC
15.5828450419
752PhosphorylationSSQASVASSQPVSSE
CCCHHHHCCCCCCHH
27.6128450419
753PhosphorylationSQASVASSQPVSSEM
CCHHHHCCCCCCHHH
28.8528450419
757PhosphorylationVASSQPVSSEMYRDP
HHCCCCCCHHHHCCC
27.5428450419
758PhosphorylationASSQPVSSEMYRDPF
HCCCCCCHHHHCCCC
26.9828450419
761PhosphorylationQPVSSEMYRDPFGNP
CCCCHHHHCCCCCCC
14.0728450419

Upstream regulatory proteins (kinases for phosphorylation sites, E3 ubiquitin ligases of ubiquitination sites, ...)
Modified Location Modified Residue Modification Type of Upstream Proteins Gene Name of Upstream Proteins UniProt AC of Upstream Proteins Sources
24SPhosphorylationKinasePRKCBP05771-2
GPS
24SPhosphorylationKinasePRKCDQ05655
GPS
24SPhosphorylationKinasePRKCGP05129
GPS
24SPhosphorylationKinasePKC-FAMILY-GPS
24SPhosphorylationKinasePKC_GROUP-PhosphoELM
723SPhosphorylationKinaseCAMK2GQ13555
PSP
723SPhosphorylationKinaseROCK2O75116
PSP

Functions of PTM Sites
Modified Location Modified Residue Modification Function Reference

Oops, there are no descriptions of PTM sites of DAB2_HUMAN !!

Disease-associated PTM Sites based on SAP

* Distance = the distance between SAP position and PTM sites.

Modified Location Modification Variant Position
(Distance <= 10)
Residue Change SAP Related Disease Reference

Oops, there are no SNP-PTM records of DAB2_HUMAN !!

Protein-Protein Interaction
Interacting Protein Gene Name Interaction Type PPI Reference Domain-Domain Interactions
DVL3_HUMANDVL3physical
12805222
DVL2_HUMANDVL2physical
12805222
DVL1_HUMANDVL1physical
12805222
AXIN1_HUMANAXIN1physical
12805222
TGFR1_HUMANTGFBR1physical
11387212
TGFR2_HUMANTGFBR2physical
11387212
LDLR_HUMANLDLRphysical
11247302
A4_HUMANAPPphysical
11247302
APLP1_HUMANAPLP1physical
11247302
APLP2_HUMANAPLP2physical
11247302
SHIP1_HUMANINPP5Dphysical
11247302
LRP1_HUMANLRP1physical
11247302
MYO6_HUMANMYO6physical
11967127
DAB2P_HUMANDAB2IPphysical
11812785
MYO6_HUMANMYO6physical
11906161
CSK_HUMANCSKphysical
12473651
SRC_HUMANSRCphysical
12473651
FGR_HUMANFGRphysical
12473651
SH3K1_HUMANSH3KBP1physical
14596919
MYO6_HUMANMYO6physical
19855435
AP2B1_HUMANAP2B1physical
22323290
FCHO2_HUMANFCHO2physical
22323290
AP2A1_HUMANAP2A1physical
22323290
MYO6_HUMANMYO6physical
22323290
ACOT9_HUMANACOT9physical
22323290
CLH1_HUMANCLTCphysical
22323290
AP2A2_HUMANAP2A2physical
22323290
NU155_HUMANNUP155physical
22323290
SC24B_HUMANSEC24Bphysical
22323290
PRDX1_HUMANPRDX1physical
22323290
AP2M1_HUMANAP2M1physical
22323290
MALT1_HUMANMALT1physical
22323290
SF3B2_HUMANSF3B2physical
22323290
CCNT1_HUMANCCNT1physical
22323290
YLPM1_HUMANYLPM1physical
22323290
SC23B_HUMANSEC23Bphysical
22323290
P5CR1_HUMANPYCR1physical
22323290
AURKA_HUMANAURKAphysical
22323290
CN166_HUMANC14orf166physical
22323290
CPSF6_HUMANCPSF6physical
22323290
HS105_HUMANHSPH1physical
22323290
TRIO_HUMANTRIOphysical
22323290
HNRPL_HUMANHNRNPLphysical
22323290
SAHH_HUMANAHCYphysical
22323290
GRB2_HUMANGRB2physical
22323290
CPSF7_HUMANCPSF7physical
22323290
ACTB_HUMANACTBphysical
22323290
FCHO2_HUMANFCHO2physical
28514442
SPB4_HUMANSERPINB4physical
28514442

Drug and Disease Associations
Kegg Disease
There are no disease associations of PTM sites.
OMIM Disease
There are no disease associations of PTM sites.
Kegg Drug
There are no disease associations of PTM sites.
DrugBank
There are no disease associations of PTM sites.
Regulatory Network of DAB2_HUMAN

loading...

Related Literatures of Post-Translational Modification
Phosphorylation
ReferencePubMed
"A quantitative atlas of mitotic phosphorylation.";
Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.;
Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-394 AND SER-401, ANDMASS SPECTROMETRY.
"Automated phosphoproteome analysis for cultured cancer cells by two-dimensional nanoLC-MS using a calcined titania/C18 biphasic column.";
Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y.;
Anal. Sci. 24:161-166(2008).
Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-151; TYR-170 ANDSER-401, AND MASS SPECTROMETRY.
"A probability-based approach for high-throughput proteinphosphorylation analysis and site localization.";
Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
Nat. Biotechnol. 24:1285-1292(2006).
Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-393; SER-394 ANDSER-401, AND MASS SPECTROMETRY.
"Global, in vivo, and site-specific phosphorylation dynamics insignaling networks.";
Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.;
Cell 127:635-648(2006).
Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-342; SER-393 ANDSER-394, AND MASS SPECTROMETRY.
"Large-scale characterization of HeLa cell nuclear phosphoproteins.";
Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,Li J., Cohn M.A., Cantley L.C., Gygi S.P.;
Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004).
Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-221; SER-227 ANDSER-401, AND MASS SPECTROMETRY.

TOP